Disclosing Drug Development Failures Would Aid Regulatory Science, FDA’s Hamburg Says
Executive Summary
FDA is making the case for increased data-sharing and disclosure about drug development failures in the name of bolstering regulatory science.
You may also be interested in...
Orphan Disclosures Could Increase Under Tweaks Proposed By FDA
Agency considering whether to tell public if sponsors have submitted annual product development reports as part of proposed rule clarifying portions of 1992 Orphan Drug Regulations.
Regulatory Reform: FDA Pushes Back, Asks For Specific Problems To Fix
FDA pushed back against a growing number of calls for regulatory reform during the U.S. Conference on Rare Diseases and Orphan Products, mainly because they were just generalized complaints.
Regulatory Reform: FDA Pushes Back, Asks For Specific Problems To Fix
FDA pushed back against a growing number of calls for regulatory reform during the U.S. Conference on Rare Diseases and Orphan Products, mainly because they were just generalized complaints.